IRCT2016041627412N1已完成2 期
Comparison of Combined Therapy with Deferoxamine and Deferiprone versus Monotherapy with Deferoxamine or Deferiprone in Iron Overloaded Thalassemia Patients
Vice Chancellor for research of Urmia University of Medical Sciences0 个研究点目标入组 36 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 3 years 至 18 years（—）
- 性别
- All
入选标准
- •Inclusion Criteria: Transfusion-dependent Thalassemia; Age more than three years; Serum ferritin level > 5,000 ng/L and progressively increasing undergoing chelating therapy with subcutaneous DFO
排除标准
- •Severe liver, kidney or cardiac disease; Serious adverse events with DFO or DFP; Neutriphil count < 2000/L during the past 2 years; Platelet count < 100,000/L; History of arthropathy
研究者
相似试验
已完成
不适用
Treatment effect of deferiprone and desferrioxamine in beta thalassemia majorIRCT138810203032N1Mazndaran University of Medical Science100
尚未招募
2 期
Efficacy and safety of triple iron chelator (deferoxamine, deferasirox, and deferiprone) versus dual iron chelator (deferoxamine and deferasirox) combination therapy for reducing iron overload in transfusion-dependent beta-thalassaemia with very high iron overload.ThalassaemiaSLCTR/2023/010Prof Anuja Premawardhena
Unknown
1 期
The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular CarcinomaHepatocellular Carcinoma Non-resectableNCT03652467Jinan Military General Hospital100
已完成
2 期
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron OverloadCardiac Iron OverloadNCT01254227Novartis Pharmaceuticals60
已完成
Unknown
Comparison of Deferazirox and Deferoxamine on Serum Ferritin Levels Changes in Major Beta Thalassemia PatientsIRCT20190817044550N4Birjand University of Medical Sciences45